AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34266802 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine + adrenaline + TXA
Number of subjects: 60
Study 34266802 — intervention group
Group type: COMPARATOR
Intervention: lidocaine + adrenaline
Number of subjects: 60
Study 34098913 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative and Stepped Care (CSC) model
Number of subjects: 24
Study 34098913 — intervention group
Group type: COMPARATOR
Intervention: Usual mental health care
Number of subjects: 24
Study 35241369 — intervention group
Group type: EXPERIMENTAL
Intervention: AC plus 0.5 µg of Vit D (Bon One 0.5 µg) orally once daily during the whole treatment course
Number of subjects: 150
Study 35241369 — intervention group
Group type: COMPARATOR
Intervention: AC (control group)
Number of subjects: 150
Study 34294101 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinyarwanda version of the PAID questionnaire
Number of subjects: 266
Study 34761610 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) after surgery
Number of subjects: 84
Study 34761610 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant radiotherapy after surgery
Number of subjects: 84
Study 32649808 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-step border molding technique using addition vinyl silicone impression material (P-group)
Number of subjects: 10
Study 32649808 — intervention group
Group type: COMPARATOR
Intervention: Sectional border molding technique using green stick compound (Z-group)
Number of subjects: 10
Study 34786906 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused extracorporeal shock wave therapy (f-ESWT) on myofascial points
Number of subjects: 30
Study 34786906 — intervention group
Group type: COMPARATOR
Intervention: Traditional focused extracorporeal shock wave therapy (ESWT) on the medial calcaneal tubercle
Number of subjects: 30
Study 33278417 — intervention group
Group type: EXPERIMENTAL
Intervention: MITRACLIP® device
Number of subjects: 14647
Study 33589725 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Video (video-assisted self-directed course)
Number of subjects: 134
Study 33589725 — intervention group
Group type: COMPARATOR
Intervention: Ins-Video (video-assisted facilitator-led course)
Number of subjects: 134
Study 33589725 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 134
Study 35442431 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT plus tDCS
Number of subjects: 148
Study 35442431 — intervention group
Group type: COMPARATOR
Intervention: CBT alone
Number of subjects: 148
Study 35442431 — intervention group
Group type: COMPARATOR
Intervention: CBT plus sham-tDCS
Number of subjects: 148
Study 33009565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (1.5% ammonium fluoride) applied every sixth week during orthodontic treatment
Number of subjects: 166
Study 33009565 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish (non-fluoride) applied every sixth week during orthodontic treatment
Number of subjects: 166
Study 33009565 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish
Number of subjects: 166
Study 33009565 — intervention group
Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 166
Study 32664177 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinect Exercise Group (N=10)
Number of subjects: 20
Study 32664177 — intervention group
Group type: COMPARATOR
Intervention: Conventional Exercise Group (N=10)
Number of subjects: 20
Study 32664177 — intervention group
Group type: COMPARATOR
Intervention: Kinect Exercise Group vs Conventional Exercise Group
Number of subjects: 20
Study 36264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative-pressure wound therapy (pNPWT) for 7 days
Number of subjects: 50
Study 36264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic negative-pressure wound therapy (pNPWT)
Number of subjects: 50
Study 36264751 — intervention group
Group type: COMPARATOR
Intervention: Control (sterile gauze dressing)
Number of subjects: 50
Study 36264751 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 34061146 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder monitoring for 12 months
Number of subjects: 300
Study 34061146 — intervention group
Group type: COMPARATOR
Intervention: External loop recorder monitoring for 30 days
Number of subjects: 300
Study 36103393 — intervention group
Group type: EXPERIMENTAL
Intervention: Local area code
Number of subjects: 685
Study 36103393 — intervention group
Group type: COMPARATOR
Intervention: Generic toll-free area code
Number of subjects: 685
Study 33825304 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.5 µg/g, group D)
Number of subjects: 120
Study 33825304 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (0.08 mg/kg, group M)
Number of subjects: 120
Study 33825304 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group C)
Number of subjects: 120
Study 35309584 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS combined with VNeST
Number of subjects: 6
Study 35309584 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation combined with VNeST
Number of subjects: 6
Study 32533354 — intervention group
Group type: EXPERIMENTAL
Intervention: SORT maneuver (sniffing position, NGT orientation, contralateral rotation, and twisting movement)
Number of subjects: 396
Study 32533354 — intervention group
Group type: COMPARATOR
Intervention: NFLP (neck flexion lateral pressure)
Number of subjects: 396
Study 32533354 — intervention group
Group type: COMPARATOR
Intervention: NFLP
Number of subjects: 396
Study 33454739 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo analgesia
Number of subjects: 0
Study 33454739 — intervention group
Group type: COMPARATOR
Intervention: Opioid antagonist
Number of subjects: 0
Study 32442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic breathlessness (mMRC scale)
Number of subjects: 2883
Study 32442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic breathlessness for two to six years
Number of subjects: 2883
Study 32442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic breathlessness attributed to cardiac failure
Number of subjects: 2883
Study 32442480 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse chronic breathlessness
Number of subjects: 2883
Study 33141065 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water (2.1 ± 0.64 °C)
Number of subjects: 10
Study 33141065 — intervention group
Group type: COMPARATOR
Intervention: Room temperature water (19.4 ± 0.5 °C)
Number of subjects: 10
Study 32484444 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Connections (intervention)
Number of subjects: 349
Study 32484444 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 349
Study 35636620 — intervention group
Group type: EXPERIMENTAL
Intervention: MicroShunt
Number of subjects: 0
Study 35636620 — intervention group
Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 0
Study 34068594 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional ability
Number of subjects: 300
Study 34068594 — intervention group
Group type: EXPERIMENTAL
Intervention: Age differences
Number of subjects: 300
Study 34068594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender differences
Number of subjects: 300
Study 32661106 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycemia, low insulin (EuLoI)
Number of subjects: 12
Study 32661106 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemia, low insulin (HyLoI)
Number of subjects: 12
Study 32661106 — intervention group
Group type: COMPARATOR
Intervention: Euglycemia, high insulin (EuHiI)
Number of subjects: 12
Study 32661106 — intervention group
Group type: COMPARATOR
Intervention: Participants without diabetes
Number of subjects: 12
Study 34808255 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic gabapentin (600 mg thrice daily)
Number of subjects: 58
Study 34808255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 33096126 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider training intervention
Number of subjects: 3216
Study 36284033 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia-guided non-culprit vessel angioplasty
Number of subjects: 109
Study 36284033 — intervention group
Group type: COMPARATOR
Intervention: Routine non-culprit vessel angioplasty
Number of subjects: 109
Study 33504042 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic physical exercise (TPE) program supervised by a physiotherapist
Number of subjects: 54
Study 32822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 10 mg once daily
Number of subjects: 825
Study 32822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg once daily
Number of subjects: 825
Study 32822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg once daily
Number of subjects: 825
Study 32822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 30 mg twice daily
Number of subjects: 825
Study 32822633 — intervention group
Group type: EXPERIMENTAL
Intervention: Atogepant 60 mg twice daily
Number of subjects: 825
Study 32822633 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study 36149220 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm fluoride and aloe vera
Number of subjects: 72
Study 36149220 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste with sodium monofluorophosphate formulation
Number of subjects: 72
Study 36149220 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups B1 and A2
Number of subjects: 72
Study 36149220 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups A3 and B3
Number of subjects: 72
Study 36149220 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B4
Number of subjects: 72
Study 34622845 — intervention group
Group type: EXPERIMENTAL
Intervention: A+HA (20 mL supplement mixture containing 50 mg HA, 750 mg glucosamine, and 250 mg chondroitin)
Number of subjects: 80
Study 34622845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 616994361 — intervention group
Group type: EXPERIMENTAL
Intervention: Education based on health belief model with relaxation
Number of subjects: 120
Study 34788698 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant and concurrent androgen deprivation therapy (ADT) for 6 months starting 4 months before prostate radiation therapy
Number of subjects: 393
Study 34788698 — intervention group
Group type: COMPARATOR
Intervention: Concurrent and adjuvant ADT for 6 months starting simultaneously with radiation therapy
Number of subjects: 393
Study 33895829 — intervention group
Group type: EXPERIMENTAL
Intervention: Height adjustment in multivariable Mendelian randomization (MVMR) analysis
Number of subjects: 0
Study 33895829 — intervention group
Group type: COMPARATOR
Intervention: Other candidate mediators (free T4, systolic blood pressure, heart rate)
Number of subjects: 0
Study 35583486 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (FLZ)
Number of subjects: 108
Study 32188492 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional treatment plus 1g of intravenous calcium gluconate (group 2)
Number of subjects: 50
Study 32188492 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (morphine 0.1 mg/kg + normal saline; group 1)
Number of subjects: 50
Study 33272766 — intervention group
Group type: EXPERIMENTAL
Intervention: SELF intervention
Number of subjects: 40
Study 33272766 — intervention group
Group type: COMPARATOR
Intervention: Waitlist-control (treatment-as-usual)
Number of subjects: 40
Study 34921023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 102
Study 34921023 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin-Pemetrexed
Number of subjects: 102
Study 35613672 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted hypoglossal nerve stimulation (activated at Month 1)
Number of subjects: 150
Study 35613672 — intervention group
Group type: COMPARATOR
Intervention: Control group (activated at Month 7)
Number of subjects: 150
Study 35613672 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life metrics
Number of subjects: 150
Study 35613672 — intervention group
Group type: EXPERIMENTAL
Intervention: Oximetry metrics
Number of subjects: 150
Study 32901283 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotta glucosamine (DONA powder sachets, 1500 mg/day)
Number of subjects: 14
Study 32901283 — intervention group
Group type: COMPARATOR
Intervention: Non-Rotta glucosamine (glucosamine sulphate 1500 mg one-a-day tablet)
Number of subjects: 14
Study 32463382 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation aromatherapy with lavender and sweet orange
Number of subjects: 96
Study 32463382 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage with lavender and sweet orange
Number of subjects: 96
Study 32463382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 35533791 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course IV antibiotics (2 weeks)
Number of subjects: 60
Study 35533791 — intervention group
Group type: COMPARATOR
Intervention: Standard-course IV antibiotics (6 weeks)
Number of subjects: 60
Study 33326848 — intervention group
Group type: EXPERIMENTAL
Intervention: Omadacycline
Number of subjects: 2112
Study 33152285 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2DX prognostic score
Number of subjects: 435
Study 35876243 — intervention group
Group type: EXPERIMENTAL
Intervention: Moral disengagement intervention
Number of subjects: 1200
Study 35876243 — intervention group
Group type: EXPERIMENTAL
Intervention: Social norms intervention
Number of subjects: 1200
Study 34732523 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA agonism
Number of subjects: 24
Study 34732523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 35365783 — intervention group
Group type: EXPERIMENTAL
Intervention: CP-LVH
Number of subjects: 2645
Study 35365783 — intervention group
Group type: EXPERIMENTAL
Intervention: SL-LVH
Number of subjects: 2645
Study 35365783 — intervention group
Group type: EXPERIMENTAL
Intervention: CV-LVH
Number of subjects: 2645
Study 35365783 — intervention group
Group type: EXPERIMENTAL
Intervention: LVH
Number of subjects: 2645
Study 33386021 — intervention group
Group type: COMPARATOR
Intervention: Microscope
Number of subjects: 22
Study 33386021 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Exoscope
Number of subjects: 22
Study 33386021 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D Exoscope
Number of subjects: 22
Study 32740306 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative intervention
Number of subjects: 80
Study 32740306 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 80
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Small group music therapy (GMT)
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational choir singing (RCS)
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of GMT and RCS
Number of subjects: 318
Study 35109491 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric symptoms
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Care staff burden
Number of subjects: 318
Study 35109491 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 318
Study 32363616 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (500 mg/day)
Number of subjects: 60
Study 32363616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 33931405 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune therapy
Number of subjects: 0
Study 33931405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32067293 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Yoga Intervention (MYI) added to Treatment as Usual (TAU)
Number of subjects: 171
Study 32067293 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 171
Study 35679200 — intervention group
Group type: EXPERIMENTAL
Intervention: Email inquiries from simulated patients
Number of subjects: 725
Study 35679200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patients with depression
Number of subjects: 725
Study 35679200 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated patients who could pay full fee
Number of subjects: 725
Study 34032866 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 720
Study 34032866 — intervention group
Group type: EXPERIMENTAL
Intervention: IPS supplemented with cognitive remediation (IPSE)
Number of subjects: 720
Study 34032866 — intervention group
Group type: COMPARATOR
Intervention: Service as Usual
Number of subjects: 720
Study 32125716 — intervention group
Group type: EXPERIMENTAL
Intervention: Consecutive controlled case series (CCCS) methodologies
Number of subjects: 0
Study 32125716 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial combining SCEDs with randomized group designs
Number of subjects: 0
Study 34915084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofilament light chain dosage (NF‐L) at thresholds of 500 pg/ml and 1,200 pg/ml added to the modified ESICM/ERC 2021 algorithm.
Number of subjects: 49
Study 34915084 — intervention group
Group type: COMPARATOR
Intervention: Unmodified ESICM/ERC 2021 algorithm without NF‐L.
Number of subjects: 49
Study 34915084 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofilament light chain (NF‐L) values for good versus poor outcomes.
Number of subjects: 49
Study 32728814 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin plus 420 nm IPL
Number of subjects: 47
Study 32728814 — intervention group
Group type: COMPARATOR
Intervention: Isotretinoin alone
Number of subjects: 47
Study 34847465 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified information intervention
Number of subjects: 20000
Study 34847465 — intervention group
Group type: COMPARATOR
Intervention: Empathetic messages
Number of subjects: 20000
Study 34847465 — intervention group
Group type: COMPARATOR
Intervention: Magnetic calendar reminder
Number of subjects: 20000
Study 34847465 — intervention group
Group type: COMPARATOR
Intervention: Combination of interventions
Number of subjects: 20000
Study 32846798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) administration [1 g] before skin incision
Number of subjects: 100
Study 32846798 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 100
Study 35610657 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic management (EG)
Number of subjects: 100
Study 35610657 — intervention group
Group type: COMPARATOR
Intervention: Surgical management (SG)
Number of subjects: 100
Study 34268723 — intervention group
Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 251
Study 34268723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 35451381 — intervention group
Group type: EXPERIMENTAL
Intervention: Mudan granules
Number of subjects: 93
Study 35451381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 34002563 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel plaster
Number of subjects: 63
Study 34002563 — intervention group
Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 63
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic characteristic prognostic model
Number of subjects: 0
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic characteristics
Number of subjects: 0
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 0
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor location
Number of subjects: 0
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: pTNM stage
Number of subjects: 0
Study 32694053 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic prediction model combined with splenic characteristics
Number of subjects: 0
Study 35158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab
Number of subjects: 16
Study 35158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (AQP4-/MOG+ subset)
Number of subjects: 16
Study 35158465 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab (AQP4-/MOG- subset)
Number of subjects: 16
Study 35158465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 33435919 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched Music-supported Therapy (eMST)
Number of subjects: 60
Study 33435919 — intervention group
Group type: COMPARATOR
Intervention: Control group (home-based exercises utilizing the Graded Repetitive Arm Supplementary Program - GRASP)
Number of subjects: 60
Study 34236037 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound renal denervation (RDN)
Number of subjects: 33
Study 34979513 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg to a maximum of 1,500 mg)
Number of subjects: 72
Study 34979513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 34979513 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (250 mg to a maximum of 1,500 mg) and Placebo
Number of subjects: 72
Study 33449316 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent process
Number of subjects: 10
Study 33449316 — intervention group
Group type: EXPERIMENTAL
Intervention: Readability of informed consent documents
Number of subjects: 10
Study 32311884 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction scoring system for hypoxemia
Number of subjects: 148
Study 34599719 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOM
Number of subjects: 258
Study 34599719 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOM plus
Number of subjects: 258
Study 34599719 — intervention group
Group type: EXPERIMENTAL
Intervention: IPOM plus + AVCS
Number of subjects: 258
Study 33707626 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic prediction based on selected subsets of SNPs from GWAS results
Number of subjects: 14827